Finanzen von Intensity Therapeutics Inc (INTS)INTSIntensity Therapeutics Inc

Evaluating the bottom line, Intensity Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.88%, provide a clear picture of how effectively INTS converts its operational activities into shareholder value.

In the context of the broader market, INTS competes directly with industry leaders such as BNGO and RGNT. With a market capitalization of $13.75M, it holds a significant position in the sector. When comparing efficiency, INTS's gross margin of N/A stands against BNGO's 52.80% and RGNT's N/A. Such benchmarking helps identify whether Intensity Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Intensity Therapeutics has been struggling financially, with a net income of -3.007 million USD for Q2 2026 and a GAAP EPS of -1.11, indicating ongoing challenges in achieving profitability. The company has also experienced a year-to-date change of -58.23%, reflecting significant declines in its stock price.